Trial Profile
VEGF expressed in aqueous humor of patients with idiopathic choroidal neovascularization and response to anti-VEGF treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 27 Jul 2016 New trial record